DELCATH SYSTEMS, INC. Logo

DELCATH SYSTEMS, INC.

Interventional oncology company treating liver cancers with targeted chemotherapy.

DCTH | US

Overview

Corporate Details

ISIN(s):
US24661P8077
LEI:
Country:
United States of America
Address:
566 QUEENSBURY AVENUE, 12804 QUEENSBURY

Description

Delcath Systems, Inc. is a commercial-stage interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company develops and commercializes proprietary products for percutaneous hepatic perfusion (PHP), a minimally-invasive procedure designed to administer high-dose chemotherapy directly to the liver while controlling systemic exposure. Its flagship product in the United States is the HEPZATO KIT™ (melphalan/hepatic delivery system), an FDA-approved drug/device combination product for treating adult patients with metastatic uveal melanoma. In Europe, the company markets the CHEMOSAT® Hepatic Delivery System, a medical device for the same procedure.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-25 22:15 English 6.7 KB
2025-11-20 22:45
8-K
English 48.7 KB
2025-11-13 17:53 English 6.6 KB
2025-11-04 15:04
10-Q
English 1.3 MB
2025-11-04 14:02
8-K
English 93.6 KB
2025-10-20 12:01
8-K
English 146.5 KB
2025-10-18 00:05 English 12.4 KB
2025-08-15 22:46
S-8
English 64.8 KB
2025-08-15 22:15
8-K
English 132.4 KB
2025-08-06 15:14
10-Q
English 1.5 MB
2025-08-06 14:03
8-K
English 92.9 KB
2025-06-13 23:22 English 7.5 KB
2025-05-22 13:15
8-K
English 66.7 KB
2025-05-19 22:10 English 7.4 KB
2025-05-19 22:10 English 7.4 KB

Automate Your Workflow. Get a real-time feed of all DELCATH SYSTEMS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DELCATH SYSTEMS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DELCATH SYSTEMS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AVACTA GROUP PLC Logo
Clinical-stage biotech developing targeted oncology drugs with a proprietary platform.
United Kingdom
AVCT
AVADEL PHARMACEUTICALS PLC Logo
Biopharmaceutical company developing therapies for sleep disorders, focusing on narcolepsy.
United States of America
AVDL
Avalon GloboCare Corp. Logo
Develops cell-based immunotherapies and provides precision diagnostics and lab services.
United States of America
ALBT
Avidity Biosciences, Inc. Logo
Develops a class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs).
United States of America
RNA
Axogen, Inc. Logo
Develops and commercializes surgical solutions for peripheral nerve repair.
United States of America
AXGN
Axsome Therapeutics, Inc. Logo
A biopharmaceutical company developing therapies for central nervous system disorders.
United States of America
AXSM
AYTU BIOPHARMA, INC Logo
A specialty pharma company developing novel therapeutics for complex CNS diseases.
United States of America
AYTU
Azitra, Inc. Logo
Clinical-stage biopharma company developing microbiome-based therapies for skin diseases.
United States of America
AZTR
Bachem Holding AG Logo
A CDMO developing and manufacturing peptides and oligonucleotides for pharma and biotech.
Switzerland
BANB
Barinthus Biotherapeutics plc. Logo
Clinical-stage biopharma developing immunotherapies that guide T cells to control disease.
United States of America
BRNS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.